Arvind Gupta co-leads Mayfield’s Engineering Biology practice whose mission is to invest in science based companies that could change history. Ranging from reinventing our food system to stopping climate change to novel therapeutics, Arvind was the first investor in breakout companies such as Geltor, Synthex, Prime Roots, NotCo, Prellis, New Culture, DNA Lite, Catalog, Prellis and Memphis Meats.
As Founder of IndieBio, Arvind redefined the pace and possibilities of early stage biotech, investing in over 136 companies in five years, defining human and planetary health, and growing the IndieBio portfolio into billions of dollars in value.
Arvind is the author of Decoding the World: A Roadmap for the Questioner. He was honored with the F50 Global Award for Impact in HealthTech Innovation.